TC BioPharm Secures CryoTC Trademark For Cell Freezing Process

TC Biopharm Ltd (NASDAQ: TCBP) has registered the U.K. trademark CryoTC for its proprietary process for freezing and thawing its lead oncology product, OmnImmune.

• CryoTR is TC BioPharm's unique cryopreservation process, which is performed in a controlled rate freezer using an optimized protocol.

• OmnImmune is an allogeneic unmodified cell therapy consisting of activated and expanded gamma delta T cells.

• OmnImmune comprises GDT cells sourced from healthy donors, activated, and expanded in large numbers before being purified, formulated, and cryopreserved for subsequent thawing and infusion into patients.

• Last month, the FDA granted Orphan Drug designation to TC Biopharm OmnImmune for use in acute myeloid leukemia.

• The company plans to initiate Phase 2/3 trial enrollment in Q1 of 2022 in the U.K., expanding into the U.S. in 2022.

• Price Action: TCBP shares are down 3.23% at $1.50 on the last check Wednesday.

See more from Benzinga

• Novartis' Breast Cancer PI3K Drug, Scores FDA Approval For Ultra-Rare Indication

• HC Wainwright Sees 'Multiple Catalyst Opportunities' After Atreca Inks Licensing Pact With Zymeworks

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.